These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27383615)

  • 1. Oesophageal lumen pH in yearling horses and effects of management and administration of omeprazole.
    Wilson CS; Brookes VJ; Hughes KJ; Trope GD; Ip H; Gunn AJ
    Equine Vet J; 2017 May; 49(3):389-394. PubMed ID: 27383615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison.
    Frazzoni M; De Micheli E; Grisendi A; Savarino V
    Aliment Pharmacol Ther; 2002 Jan; 16(1):35-9. PubMed ID: 11856076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of GastroGard and three compounded oral omeprazole preparations on 24 h intragastric pH in gastrically cannulated mature horses.
    Merritt AM; Sanchez LC; Burrow JA; Church M; Ludzia S
    Equine Vet J; 2003 Nov; 35(7):691-5. PubMed ID: 14649361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morning or evening dosage of omeprazole for gastro-oesophageal reflux disease?
    Hendel J; Hendel L; Aggestrup S
    Aliment Pharmacol Ther; 1995 Dec; 9(6):693-7. PubMed ID: 8824658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of different doses of omeprazole on 24-hour oesophageal acid exposure in patients with gastro-oesophageal reflux.
    Robinson M; Maton PN; Allen ML; Humphries TJ; McIntosh D; Cagliola AJ; Bradstreet TE
    Aliment Pharmacol Ther; 1991 Dec; 5(6):645-51. PubMed ID: 1782307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.
    Newton M; Burnham WR; Kamm MA
    Eur J Gastroenterol Hepatol; 1998 Sep; 10(9):753-8. PubMed ID: 9831269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of omeprazole or anti-reflux surgery on lower oesophageal sphincter characteristics and oesophageal acid exposure over 10 years.
    Emken BG; Lundell LR; Wallin L; Myrvold HE; Engström C; Montgomery M; Malm AR; Lind T; Hatlebakk JG;
    Scand J Gastroenterol; 2017 Jan; 52(1):11-17. PubMed ID: 27593706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant Administration of a Histamine2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression.
    Abdul-Hussein M; Freeman J; Castell D
    Pharmacotherapy; 2015 Dec; 35(12):1124-9. PubMed ID: 26621819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors.
    Katz PO; Anderson C; Khoury R; Castell DO
    Aliment Pharmacol Ther; 1998 Dec; 12(12):1231-4. PubMed ID: 9882031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease.
    Robinson M; Maton PN; Rodriguez S; Greenwood B; Humphries TJ
    Aliment Pharmacol Ther; 1997 Oct; 11(5):973-80. PubMed ID: 9354209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of intra-oesophageal pH in patients with Barrett's oesophagus on omeprazole-sodium bicarbonate therapy.
    Gerson LB; Mitra S; Bleker WF; Yeung P
    Aliment Pharmacol Ther; 2012 Apr; 35(7):803-9. PubMed ID: 22356659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients.
    Calabrese C; Liguori G; Gabusi V; Gionchetti P; Rizzello F; Straforini G; Brugnera R; Di Febo G
    Aliment Pharmacol Ther; 2008 Jul; 28(2):250-5. PubMed ID: 18485128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of omeprazole on oesophageal pH in dogs during anaesthesia.
    Panti A; Bennett RC; Corletto F; Brearley J; Jeffery N; Mellanby RJ
    J Small Anim Pract; 2009 Oct; 50(10):540-4. PubMed ID: 19796313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy.
    Basu KK; Bale R; West KP; de Caestecker JS
    Eur J Gastroenterol Hepatol; 2002 Nov; 14(11):1187-92. PubMed ID: 12439112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
    Castell D; Bagin R; Goldlust B; Major J; Hepburn B
    Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy.
    Peters FT; Kuipers EJ; Ganesh S; Sluiter WJ; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
    Aliment Pharmacol Ther; 1999 Jul; 13(7):921-6. PubMed ID: 10383527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity.
    Orr WC; Harnish MJ
    Aliment Pharmacol Ther; 2003 Jun; 17(12):1553-8. PubMed ID: 12823159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
    Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
    Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, acceptability and endoscopic findings in foals and yearling horses treated with a paste formulation of omeprazole for twenty-eight days.
    Murray MJ; Eichorn ES; Holste JE; Cox JL; Stanier WB; Cooper WL; Cooper VA
    Equine Vet J Suppl; 1999 Apr; (29):67-70. PubMed ID: 10696298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
    Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.